Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Recruiting
Phase: Phase 3
Diagnosis: Multiple Myeloma
NCT ID: NCT01734928 (View complete trial on
DFCI Protocol ID:


The purpose of this study is to compare the efficacy of the combination of Pomalidomide, Bortezomib and Dexamethasone to the combination of Bortezomib and Dexamethasone in patients with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of Pomalidomide, Bortezomib and Dexamethasone is compared to the combination of Bortezomib and Dexamethasone


Conducting Institutions:
Beth-Israel Deaconess Medical Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital

Overall PI:
Jacalyn Rosenblatt, MD, Beth Israel Deaconess Medical Center

Site-responsible Investigators:
Paul Richardson, MD, Dana-Farber Cancer Institute
Andrew Yee, MD, Massachusetts General Hospital

Beth-Israel Deaconess Medical Center: Cancer Trials Call Center, 617-667-3060
Dana-Farber Cancer Institute: Deborah Doss, 617-632-5672,
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Inclusion Criteria: - Must be ≥ 18yrs at the time of signing informed consent. - Must have documented diagnosis of multiple myeloma and have measureable disease by serum and urine protein electrophoresis. - Must have had at least 1 but no greater than 3 prior anti-myeloma regimens. - Must have documented disease progression during or after their last anti-myeloma therapy. - All subjects must have received prior treatment with a lenalidomide containing regimen for at least 2 consecutive cycles. Exclusion Criteria: - Refractory to prior Bortezomib-containing therapy under the 1.3 mg/m2 dose twice weekly dosing schedule. - Peripheral neuropathy Grade 3, Grade 4 or Grade 2 with pain within 14 days prior to randomization. - Non-secretory multiple myeloma. - Subjects with severe renal impairment requiring dialysis. - Previous therapy with pomalidomide.
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online